CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities LUND, Sweden, June 18, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced topline...
Read More Details
Finally We wish PressBee provided you with enough information of ( Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients )
Also on site :